



Going Beyond Surgery: The Latest Updates in Identification and Medical Management of Cushing Syndrome

Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens*. 1994;12:609-615.

Araujo-Castro M, Iriarte-Durán MB, Parra-Ramírez P, Donato S. Management of adrenal incidentalomas: who, why and how? *Curr Opin Endocrinol Diabetes Obes*. 2025 Oct 1;32(5):210-221.

Aresta C, Soranna D, Giovanelli L, et al. When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. *Endocr Pract*. 2021;27(12):1216-1224.

Bancos I, Castinetti F, Brevoort Geer E, et al. SUN-054 Long-Term, Real-World, Safety and Effectiveness of Osilodrostat In Patients With Pituitary and Non-Pituitary Cushing's Syndrome: 2-Year Interim Data From LINC 6. *J Endocr Soc*. 2025;9(Suppl 1):bvaf149.1639.

Bancos I, Alahdab F, Crowley RK, et al. THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. *Eur J Endocrinol*. 2016;175(6):R283-R295.

Bhatt DL, Taub P, Laffin L, et al. Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Presented at American College of Cardiology's Annual Scientific Session (ACC.26). March 27-30, 2026. New Orleans, LA. Available at: [ACC 75th Annual Scientific Sessions - Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study](#). Accessed April 1, 2026.

Braun LT, Vogel F, Zopp S, et al. Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. *J Clin Endocrinol Metab*. 2022;107(9):e3723-e3730.

Braun LT, Vogel F, Nowak E, et al. Frequency of clinical signs in patients with Cushing's syndrome and mild autonomous cortisol secretion: overlap is common. *Eur J Endocrinol*. 2024;191(4):473-479.

Buse JB, Kahn SE, Aroda VR, et al; CATALYST Investigators*. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. *Diabetes Care*. 2025;48(12):2012-2020.

Chiodini I, Vainicher CE, Morelli V, et al. MECHANISMS IN ENDOCRINOLOGY: Endogenous subclinical hypercortisolism and bone: a clinical review. *Eur J Endocrinol*. 2016;175(6):R265-R282.

Chiodini I, Mascia ML, Muscarella S, et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. *Ann Intern Med*. 2007;147(8):541-548.

Cohan P. Pasireotide and mifepristone: new options in the medical management of Cushing's disease. *Endocr Pract*. 2014;20(1):84-93

Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. *N Engl J Med*. 2012;366(10):914-924.

DeFronzo RA, Fonseca V, Aroda VR, et al, CATALYST Investigators*; Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. *Diabetes Care*. 2025;48(12):2036-2044.

Deutschbein T, Reimondo G, Di Dalmazi G, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. *Lancet Diabetes Endocrinol*. 2022;10(7):499-508.



Going Beyond Surgery: The Latest Updates in Identification and Medical Management of Cushing Syndrome

Fallo F, Di Dalmazi G, Beuschlein F, et al. Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *J Hypertens*. 2022;40(11):2085-2101.

Feelders RA, Fleseriu M, Kadioglu P, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. *Front Endocrinol (Lausanne)*. 2023;14:1165681.

Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing's syndrome. *Lancet Diabetes Endocrinol*. 2019;7(4):300-312.

Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, et al. An individualized approach to the management of Cushing disease. *Nat Rev Endocrinol*. 2023;19(10):581-599.

Fleseriu M, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol*. 2021;9:847-875.

Fleseriu M, et al. Effect of dosing and titration of osilodrostat on efficacy and safety in patients with Cushing's disease (CD): Results from two phase III trials (LINC3 and LINC4). Presented at AACE 2021. Available at: <https://www.eventscribe.net/2021/AACE/index.asp?presTarget=1657244>.

Fleseriu M, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. *Lancet Diabetes Endocrinol*. 2019;7:855-865.

Fleseriu M, Biller BM, Findling JW, et al; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. *J Clin Endocrinol Metab*. 2012;97(6):2039-49.

Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing's syndrome. *Lancet*. 2023;402(10418):2237-2252.

Gadelha M, Snyder PJ, Witek P, et al. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension. *Front Endocrinol (Lausanne)*. 2023;14:1236465.

Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. *J Clin Endocrinol Metab*. 2022;107(7):e2882-e2895.

Giovanelli L, Aresta C, Favero V, et al. Hidden hypercortisolism: a too frequently neglected clinical condition. *J Endocrinol Invest*. 2021;44(8):1581-1596.

Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M. Medical Management of Cushing's Syndrome: Current and Emerging Treatments. *Drugs*. 2019;79(9):935-956.

Kann P, Laudes M, Piepkorn B, et al. Suppressed Levels of Serum Cortisol Following High-Dose Oral Dexamethasone Administration Differ between Healthy Postmenopausal Females and Patients with Established Primary Vertebral Osteoporosis. *Clin Rheumatol*. 2001;20(1):25-29.

Lacroix A, Gu F, Gallardo W, et al; Pasireotide G2304 Study Group. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. *Lancet Diabetes Endocrinol*. 2018;6(1):17-26.

Martino M, Aboud N, Lucchetti B, et al. An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options? *Expert Opin Pharmacother*. 2023;24(5):557-576.



Going Beyond Surgery: The Latest Updates in Identification and Medical Management of Cushing Syndrome

Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. *J Hypertens*. 2012;30(5):967-73.

Nieman LK, Castinetti F, Newell-Price J, et al. Cushing syndrome. *Nat Rev Dis Primers*. 2025;11(1):4.

Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. *Eur J Endocrinol*. 2015;173(4):M33-M38.

Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2008;93(5):1526-1540.

Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. *Hypertens Res*. 2004;27(3):193-202.

Paschou SA, Kandaraki E, Dimitropoulou F, et al. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. *Endocrine*. 2016;51(2):225-235.

Pivonello R, Arnaldi G, Auchus RJ, et al; GRACE Study Investigators. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. *Lancet Diabetes Endocrinol*. 2026:S2213-8587(25):00362-00366.

Pivonello R, Arnaldi G, Auchus R, et al. Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study. *Endocrine Abstracts*. 2025;110:P69.

Pivonello R, Arnaldi G, Auchus RJ, et al. 9323 Open-label Results From Grace, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome). *J Endocr Soc*. 2024;8(Suppl 1):bvae163.1287.

Pivonello R, Zacharieva S, Elenkova A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). *Pituitary*. 2022;25(6):911-926.

Pivonello R, Bancos I, Feelders RA, et al. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. *Front Endocrinol*. 2021;12:555894.

Pivonello R, Fleseriu M, Newell-Price J, et al; LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. *Lancet Diabetes Endocrinol*. 2020;8(9):748-761.

Pivonello R, Ferrigno R, De Martino MC, Set al. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. *Front Endocrinol (Lausanne)*. 2020 8;11:648.

Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol*. 2016;4(7):611-629.

Plutzky J, Taub PR, Bhatt DL, et al. Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design. *JACC Adv*. 2026;5(3):102596.

Pugliese F, Salcuni AS, Battista C, et al. Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases. *Endocrine*. 2021;73(1):203-208.



Going Beyond Surgery: The Latest Updates in Identification and Medical Management of Cushing Syndrome

Reincke M, Fleseriu M. Cushing Syndrome: A Review. *JAMA*. 2023;330(2):170-181.

Samson SL. Long-term Medical Treatment of Cushing's Disease with Pasireotide: A Review of Current Evidence and Clinical Experience. *Clin Endocrinol Diabetes*. 2014;122(8):445-450.

Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. *Endocr Pract*. 2026:S1530-891X(26)00022-4.

Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. *Pituitary*. 2016;19(5):536-543.

Steffensen C, Dekkers OM, Lyhne J, et al. Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. *Horm Metab Res*. 2019;51(1):62-68.

Steffensen C, Pereira AM, Dekkers OM, Jørgensen JO. DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. *Eur J Endocrinol*. 2016;175(6):R247-R253.

Trifanescu R, Carsote M, Caragheorgheopol A, et al. Screening for secondary endocrine hypertension in young patients. *Maedica (Bucur)*. 2013;8(2):108-15.

van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. *Eur J Endocrinol*. 2020;182(1):11-21.

Wang L, Li N, Yao X, et al. Detection of Secondary Causes and Coexisting Diseases in Hypertensive Patients: OSA and PA Are the Common Causes Associated with Hypertension. *Biomed Res Int*. 2017;2017:8295010.